Sort by
Items per page

Send to

Choose Destination

Search results

Items: 18


ARN-509: a novel antiandrogen for prostate cancer treatment.

Clegg NJ, Wongvipat J, Joseph JD, Tran C, Ouk S, Dilhas A, Chen Y, Grillot K, Bischoff ED, Cai L, Aparicio A, Dorow S, Arora V, Shao G, Qian J, Zhao H, Yang G, Cao C, Sensintaffar J, Wasielewska T, Herbert MR, Bonnefous C, Darimont B, Scher HI, Smith-Jones P, Klang M, Smith ND, De Stanchina E, Wu N, Ouerfelli O, Rix PJ, Heyman RA, Jung ME, Sawyers CL, Hager JH.

Cancer Res. 2012 Mar 15;72(6):1494-503. doi: 10.1158/0008-5472.CAN-11-3948. Epub 2012 Jan 20.


Non-redundant roles for LXRalpha and LXRbeta in atherosclerosis susceptibility in low density lipoprotein receptor knockout mice.

Bischoff ED, Daige CL, Petrowski M, Dedman H, Pattison J, Juliano J, Li AC, Schulman IG.

J Lipid Res. 2010 May;51(5):900-6. doi: 10.1194/jlr.M900096.


Macrophage liver X receptor is required for antiatherogenic activity of LXR agonists.

Levin N, Bischoff ED, Daige CL, Thomas D, Vu CT, Heyman RA, Tangirala RK, Schulman IG.

Arterioscler Thromb Vasc Biol. 2005 Jan;25(1):135-42. Epub 2004 Nov 11.


Promoter-specific roles for liver X receptor/corepressor complexes in the regulation of ABCA1 and SREBP1 gene expression.

Wagner BL, Valledor AF, Shao G, Daige CL, Bischoff ED, Petrowski M, Jepsen K, Baek SH, Heyman RA, Rosenfeld MG, Schulman IG, Glass CK.

Mol Cell Biol. 2003 Aug;23(16):5780-9.


Farnesoid X receptor regulates bile acid-amino acid conjugation.

Pircher PC, Kitto JL, Petrowski ML, Tangirala RK, Bischoff ED, Schulman IG, Westin SK.

J Biol Chem. 2003 Jul 25;278(30):27703-11. Epub 2003 May 16.


Identification of macrophage liver X receptors as inhibitors of atherosclerosis.

Tangirala RK, Bischoff ED, Joseph SB, Wagner BL, Walczak R, Laffitte BA, Daige CL, Thomas D, Heyman RA, Mangelsdorf DJ, Wang X, Lusis AJ, Tontonoz P, Schulman IG.

Proc Natl Acad Sci U S A. 2002 Sep 3;99(18):11896-901. Epub 2002 Aug 22.


Regulation of cholesterol homeostasis and lipid metabolism in skeletal muscle by liver X receptors.

Muscat GE, Wagner BL, Hou J, Tangirala RK, Bischoff ED, Rohde P, Petrowski M, Li J, Shao G, Macondray G, Schulman IG.

J Biol Chem. 2002 Oct 25;277(43):40722-8. Epub 2002 Aug 21.


Tumor prevention by 9-cis-retinoic acid in the N-nitroso-N-methylurea model of mammary carcinogenesis is potentiated by the pineal hormone melatonin.

Nowfar S, Teplitzky SR, Melancon K, Kiefer TL, Cheng Q, Dwived PD, Bischoff ED, Moro K, Anderson MB, Dai J, Lai L, Yuan L, Hill SM.

Breast Cancer Res Treat. 2002 Mar;72(1):33-43.


Efficacy of LGD1069 (Targretin), a retinoid X receptor-selective ligand, for treatment of uterine leiomyoma.

Gamage SD, Bischoff ED, Burroughs KD, Lamph WW, Gottardis MM, Walker CL, Fuchs-Young R.

J Pharmacol Exp Ther. 2000 Nov;295(2):677-81.


Effect of the retinoid X receptor-selective ligand LGD1069 on mammary carcinoma after tamoxifen failure.

Bischoff ED, Heyman RA, Lamph WW.

J Natl Cancer Inst. 1999 Dec 15;91(24):2118.


Novel nonsecosteroidal vitamin D mimics exert VDR-modulating activities with less calcium mobilization than 1,25-dihydroxyvitamin D3.

Boehm MF, Fitzgerald P, Zou A, Elgort MG, Bischoff ED, Mere L, Mais DE, Bissonnette RP, Heyman RA, Nadzan AM, Reichman M, Allegretto EA.

Chem Biol. 1999 May;6(5):265-75.


Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW.

Cancer Res. 1998 Feb 1;58(3):479-84.


Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists.

Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA.

Nature. 1997 Mar 27;386(6623):407-10.


A novel retinoic acid receptor-selective retinoid, ALRT1550, has potent antitumor activity against human oral squamous carcinoma xenografts in nude mice.

Shalinsky DR, Bischoff ED, Lamph WW, Zhang L, Boehm MF, Davies PJ, Nadzan AM, Heyman RA.

Cancer Res. 1997 Jan 1;57(1):162-8.


Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

Gottardis MM, Bischoff ED, Shirley MA, Wagoner MA, Lamph WW, Heyman RA.

Cancer Res. 1996 Dec 15;56(24):5566-70.


Enhanced antitumor efficacy of cisplatin in combination with ALRT1057 (9-cis retinoic acid) in human oral squamous carcinoma xenografts in nude mice.

Shalinsky DR, Bischoff ED, Gregory ML, Lamph WW, Heyman RA, Hayes JS, Thomazy V, Davies PJ.

Clin Cancer Res. 1996 Mar;2(3):511-20.


Retinoid-induced suppression of squamous cell differentiation in human oral squamous cell carcinoma xenografts (line 1483) in athymic nude mice.

Shalinsky DR, Bischoff ED, Gregory ML, Gottardis MM, Hayes JS, Lamph WW, Heyman RA, Shirley MA, Cooke TA, Davies PJ, et al.

Cancer Res. 1995 Jul 15;55(14):3183-91.

Supplemental Content

Loading ...
Support Center